Dipeptidyl Peptidase 4 in Women with Polycystic Ovarian Syndrome
DOI:
https://doi.org/10.37506/mlu.v20i4.1954Keywords:
Polycystic, Dipeptidyl, DPP4, (PCOS)Abstract
Background: Polycystic ovary syndrome (PCOS) is the most prevalent reproductive endocrinopathy and
currently considered to be a part of the metabolic syndrome. Women suffering from PCOS present with a
group of symptoms related with menstrual disorder and androgen excess. Women with PCOS cluster risk
factors associated with risk of insulin resistance, dyslipidemia, hyperandrogenemia, obesity, cardiovascular
disease (CVD), infertility, and psychological disorders. Objective :The study was designed to determine the
levels of DPP4 in PCOS patients and compared with control and study the correlation with biomarkers in
serum of PCOS patients.
Subjects and Method: The study is case-control included 80 females and carried out from February
2019 till May 2019 for females in the reproductive age [18-45 years old], forty females were came from
gynecological and obstetric hospital, in Karbala, and they all diagnosed by their physicians have polycystic
ovarian syndrome and compared with forty control females {healthy females]. plasma activity of DPP4 and
biochemical variables were performed.
Results: Results obtained in this study showed that there are significant differences (p < 0.05) in serum of
DPP4, SHBG, DHEA-S, LH, FSH, free testosterone and total testosterone and there is positive significant
correlation between DPP4 with free testosterone, SHBG, DHEA-S, LH and total testosterone.
Conclusion: Polycystic ovarian syndrome is a higher risk of type 2 diabetic mellitus, dyslipidemia and
cardiovascular diseases, Dipeptidyl peptidase 4 (DPP4) was high in PCOS patient and had positive
correlation with free testosterone, total testosterone, DHEA-S, SHBG and LH.